Core Insights - Lexicon Pharmaceuticals (LXRX) shares increased by 5.1% following the announcement that Novo Nordisk (NVO) has initiated a phase I study of LX9851, an oral non-incretin obesity treatment candidate [1][6]. Group 1: Study and Mechanism - The phase I study will assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of LX9851 in 96 participants with overweight or obesity, with completion expected in Q1 2027 [2]. - LX9851 is a selective oral inhibitor of ACSL5, which plays a crucial role in fat accumulation and energy balance, and may enhance satiety by slowing gastric emptying [3]. Group 2: Preclinical Results - In preclinical studies, LX9851 combined with Novo Nordisk's Wegovy (semaglutide) resulted in greater weight loss and reduced food intake compared to Wegovy alone, and it also limited weight regain and improved liver steatosis post-Wegovy discontinuation [4]. Group 3: Licensing Agreement - Lexicon Pharmaceuticals entered an exclusive licensing agreement with Novo Nordisk in early 2025, receiving a $45 million upfront payment and a $10 million milestone payment [5]. - Under the agreement, Novo Nordisk will manage all regulatory, development, and commercialization activities for LX9851, while Lexicon will supply the drug for clinical use at a pre-agreed price [7]. Group 4: Financial Potential - Lexicon Pharmaceuticals could earn up to $1 billion in milestone payments and royalties from the deal with Novo Nordisk, with additional milestone payments already received [6][8]. Group 5: Market Context - Oral obesity therapies like LX9851 are anticipated to provide a more convenient and potentially lower-cost alternative to injectable treatments, which may enhance patient adherence [9]. Group 6: Other Developments - Lexicon's commercial portfolio includes Inpefa (sotagliflozin), approved for heart failure, and it is also evaluating sotagliflozin for type I diabetes and chronic kidney disease, with a potential resubmission for regulatory approval targeted for 2026 [10][11][13].

Group 1 - The study is focused on investigating the safety and tolerability of LX9851 [1] - The research examines how LX9851 moves through the body [1] - The physiological and biological impacts of LX9851 are being assessed [1]

Core Insights - Lexicon Pharmaceuticals and Novo Nordisk are collaborating on LX9851, an oral non-incretin candidate for obesity and metabolic disorders, with Novo Nordisk initiating a Phase 1 study [1][4] - Lexicon has received a second $10 million milestone payment from Novo Nordisk and is eligible for up to $1 billion in total payments, including royalties on net sales [3] Group 1: LX9851 Development - LX9851 is a first-in-class oral small molecule inhibitor of Acyl CoA Synthetase 5 (ACSL5), which regulates fat accumulation and energy balance [5] - The Phase 1 study will assess safety, tolerability, pharmacokinetics, and pharmacodynamics in 96 participants with overweight or obesity, expected to complete in Q1 2027 [4] Group 2: Financial Aspects - Lexicon is eligible for a total of three $10 million milestone payments, with the second payment received in 2026 following initial dosing in the Phase 1 study [3] - The collaboration agreement allows Lexicon to receive up to $1 billion in upfront and milestone payments, along with tiered royalties on net sales of LX9851 [2][3] Group 3: Company Perspectives - Lexicon's CEO expressed enthusiasm about the progress made by Novo Nordisk in advancing LX9851, highlighting its potential as a differentiated treatment for obesity [4] - Novo Nordisk's Senior Vice President emphasized the novel approach of LX9851 in treating obesity and related metabolic conditions, marking it as a significant addition to their pipeline [4]

Lexicon Pharmaceuticals Conference Call Summary Company Overview - **Company**: Lexicon Pharmaceuticals (NasdaqGS:LXRX) - **Date**: March 11, 2026 - **Event**: Leerink Global Healthcare Conference Strategic Focus and Goals - **Refocused Strategy**: In 2025, the company shifted its focus towards its R&D pipeline, particularly in cardiometabolic disease and chronic pain, especially neuropathic pain [6][7] - **Key Programs**: - **Sotagliflozin**: Phase 3 trial in hypertrophic cardiomyopathy (HCM) is enrolling well, with completion expected by mid-2026 and data readout in Q1 2027 [6][7] - **Zynquista**: Plans to resubmit NDA for glycemic control in type 1 diabetes, aiming for approval within the year [7][8] - **Pilavapadin**: Completed Phase 2 for diabetic peripheral neuropathic pain, moving to pivotal trials with no additional studies required for addiction potential [9][10] - **LX9851**: Licensed to Novo Nordisk for obesity management, with milestone payments expected as it progresses through human trials [10][11] Enrollment and Trial Design - **HCM Trial Design**: The trial includes both obstructive and non-obstructive patients, with broad entry criteria to facilitate enrollment [13][14] - **Enrollment Progress**: Enrollment is meeting expectations due to significant unmet needs in both patient groups and lack of competing trials [16][17] - **Regulatory Discussions**: The trial design has been informed by FDA guidance, focusing on KCCQ as a primary endpoint, which is recognized for its clinical relevance [18][19][21] Mechanism of Action - **Sotagliflozin's Mechanism**: It targets diastolic dysfunction, providing a novel approach compared to existing treatments for HCM, which are primarily hemodynamic [31][34] - **Complementary Role**: Sotagliflozin is seen as a potential first-line oral treatment, with benefits on both heart function and glycemic control [33][36] Regulatory Path and Challenges - **Zynquista Resubmission**: The FDA has indicated the need for new prospective data, which is being gathered through an ongoing trial in Denmark [55][56] - **Pilavapadin Phase 3 Design**: The FDA has agreed on the trial design, focusing on a 12-week ADPS score as the primary endpoint [42][43] Partnerships and Future Outlook - **Novo Nordisk Partnership**: The collaboration on LX9851 is progressing well, with Novo prioritizing the program and triggering milestone payments [62][63] - **Focus Areas**: The company is prioritizing HCM and Zynquista submissions, viewing these as significant opportunities for growth [70][71] Additional Insights - **Regulatory Environment**: The FDA's recent guidance on non-opioid chronic pain drug development aligns with Lexicon's approach, emphasizing the need for statistical significance in trial outcomes [48][49] - **Market Positioning**: Lexicon aims to differentiate its products in a competitive landscape, particularly in the obesity treatment space with unique mechanisms of action [66][67]

Financial Data and Key Metrics Changes - Total revenues for Q4 2025 were $5.5 million, compared to $49.8 million for the full year, with a significant portion coming from licensing revenue of $4.3 million from Novo Nordisk [23] - Research and development expenses decreased to $11.3 million in Q4 2025 from $26.7 million in Q4 2024, and full year expenses dropped to $61.1 million from $84.5 million [24] - Selling, general and administrative expenses for Q4 2025 were $8.8 million, down from $32.3 million in Q4 2024, with full year expenses decreasing to $37.3 million from $143.1 million [24][25] - Net loss for Q4 2025 was $15.5 million or $0.04 per share, compared to a net loss of $33.8 million or $0.09 per share in Q4 2024 [25] - As of December 31, 2025, cash investments and restricted cash totaled $125.2 million, down from $238 million at the end of 2024 [26] Business Line Data and Key Metrics Changes - The company is advancing three late-stage programs: sotagliflozin for cardiometabolic disease, pilavapadin for chronic pain, and LX9851 for obesity [4][5] - Sotagliflozin is in late-stage development for hypertrophic cardiomyopathy (HCM) and type 1 diabetes, with an NDA resubmission expected in 2026 [6][12] - Pilavapadin is phase 3-ready for diabetic peripheral neuropathic pain (DPNP), with a successful end of Phase II meeting with the FDA [20][21] Market Data and Key Metrics Changes - The company is focusing on the cardiometabolic disease and chronic pain markets, with significant unmet needs in both areas [9][11] - There are approximately 1 million patients with type 1 diabetes in the U.S., highlighting the market potential for Zynquista if approved [17][18] Company Strategy and Development Direction - The company aims to maintain operational discipline and improve its financial position to support core programs [7] - A partnership strategy is in place to support existing collaborations and explore new partnerships, particularly for pilavapadin [6][19] - The company is focused on driving multiple pivotal milestones in 2026 across its core programs [30] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's progress and the potential for significant value creation from upcoming catalysts [30] - The company is optimistic about completing enrollment in the SONATA-HCM trial and anticipates data readouts in 2027 [66][67] Other Important Information - The company has reduced total debt by approximately $46.3 million in 2025, primarily using proceeds from the Novo Nordisk upfront payment [28] - Operating expenses were reduced by $39 million in Q4 2025 compared to Q4 2024, reflecting strategic repositioning [28] Q&A Session Summary Question: What is the status of the Steno-1 study data for DKA safety? - Management expects a 6-month review for the NDA resubmission and is tracking data that gives confidence in submission and approval timelines [33][34] Question: How have the Phase 2 results impacted partnership discussions for pilavapadin? - Discussions with potential partners are ongoing, and the end of Phase 2 meeting has provided confidence around moving into Phase 3 [39][40] Question: What are Novo Nordisk's plans for LX9851? - The company believes Novo is exploring various options for LX9851, including its use in combination therapies for obesity management [41][42] Question: Is there flexibility to start the pilavapadin study without a partner? - The company is focused on cardiometabolic opportunities and is preparing for the Phase 3 program while engaging in partnership discussions [48][49] Question: What changes will be made to the Phase 3 design of pilavapadin? - The company plans to expand enrollment criteria and improve patient training on pain score assessments to mitigate placebo response [70][73]

Financial Data and Key Metrics Changes - Total revenues for Q4 2025 were $5.5 million, compared to $49.8 million for the full year 2025, reflecting a decrease from $25 million in upfront payments received in 2024 [23][24] - Research and development expenses decreased to $11.3 million in Q4 2025 from $26.7 million in Q4 2024, and full year R&D expenses decreased to $61.1 million from $84.5 million in 2024 [24] - Selling, general and administrative expenses for Q4 2025 decreased to $8.8 million from $32.3 million in Q4 2024, with full year SG&A expenses down to $37.3 million from $143.1 million in 2024 [24][25] - Net loss for Q4 2025 was $15.5 million or $0.04 per share, compared to a net loss of $33.8 million or $0.09 per share in Q4 2024 [25][26] - As of December 31, 2025, cash investments and restricted cash totaled $125.2 million, down from $238 million at the end of 2024 [26] Business Line Data and Key Metrics Changes - The company is advancing three late-stage programs: sotagliflozin for cardiometabolic disease, LX9851 for obesity, and pilavapadin for chronic pain [5][20] - Sotagliflozin is in late-stage development for hypertrophic cardiomyopathy (HCM) and type 1 diabetes, with an NDA resubmission planned for 2026 [6][12] - LX9851 has triggered a $10 million milestone payment from Novo Nordisk, with potential for additional milestones in 2026 [19] - Pilavapadin is phase III-ready for diabetic peripheral neuropathic pain, with a successful end of Phase II meeting with the FDA [21][22] Market Data and Key Metrics Changes - The company is focusing on the cardiometabolic disease and chronic pain markets, with significant unmet needs in both areas [11][20] - There are approximately 1 million patients with type 1 diabetes in the U.S., highlighting the market potential for Zynquista if approved [17][18] - The SONATA-HCM trial is the only registrational trial currently enrolling patients with both obstructive and non-obstructive HCM [14][15] Company Strategy and Development Direction - The company aims to maintain operational discipline and focus on high-value opportunities while exploring new partnerships [6][7] - A clear goal for 2026 includes advancing core programs and achieving multiple upcoming catalysts [30] - The company is committed to improving its financial position and cost structure to support long-term growth [5][7] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's momentum entering 2026, with several pivotal milestones ahead [30][31] - The company is excited about the potential of its pipeline to address serious unmet medical needs [30] - Management highlighted the importance of ongoing discussions with potential partners for pilavapadin and the strategic focus on cardiometabolic opportunities [49][50] Other Important Information - The company has completed over 50% enrollment in the SONATA-HCM Phase III study and expects to complete enrollment by mid-2026 [8][64] - The FDA has confirmed that the Steno-1 study data may support a resubmission of the NDA for Zynquista in type 1 diabetes [17][34] Q&A Session Summary Question: What is the current status of the Steno-1 study data for DKA safety? - Management expects a 6-month review for the NDA resubmission and is confident in the data supporting submission and approval timelines [33][34] Question: How have the Phase II results impacted partnership discussions for pilavapadin? - Management indicated that while discussions are ongoing, the Phase II results have provided confidence to potential partners regarding the program's advancement [39][40] Question: What are the enrollment criteria changes for the Phase III pilavapadin program? - The company plans to expand enrollment criteria and focus on training patients for consistent pain score reporting [70][72]

Financial Data and Key Metrics Changes - Total revenues for Q4 2025 were $5.5 million, and for the full year 2025, revenues were $49.8 million, compared to $25 million in upfront payment from Viatris in 2024 [24][26] - Research and development expenses decreased to $11.3 million in Q4 2025 from $26.7 million in 2024, and full year R&D expenses decreased to $61.1 million from $84.5 million [25] - Selling, general and administrative expenses for Q4 2025 decreased to $8.8 million from $32.3 million in 2024, and full year SG&A expenses decreased to $37.3 million from $143.1 million [25] - Net loss for Q4 2025 was $15.5 million or $0.04 per share, compared to a net loss of $33.8 million or $0.09 per share in Q4 2024 [26] - As of December 31, 2025, cash investments and restricted cash totaled $125.2 million, down from $238 million at the end of 2024 [27] Business Line Data and Key Metrics Changes - The company is advancing three late-stage programs: sotagliflozin for cardiometabolic disease, pilavapadin for chronic pain, and LX9851 for obesity [4][5] - Sotagliflozin is in late-stage development for hypertrophic cardiomyopathy (HCM) and type 1 diabetes, with an NDA resubmission expected in 2026 [6][18] - Pilavapadin is phase 3-ready for diabetic peripheral neuropathic pain (DPNP), with a successful end of Phase 2 meeting with the FDA [20][22] Market Data and Key Metrics Changes - The company is focusing on the cardiometabolic disease and chronic pain markets, with significant unmet needs in both areas [10][12] - There are approximately 1 million patients with type 1 diabetes in the U.S., with no new therapies approved for over a century [18] - The SONATA-HCM Phase 3 study is the only registrational trial currently enrolling patients with both obstructive and non-obstructive HCM [14][15] Company Strategy and Development Direction - The company aims to maintain operational discipline and improve its financial position to support core programs [8] - A partnership strategy is in place to support existing licensees and explore new partnerships, particularly for pilavapadin [7] - The company is focused on driving multiple pivotal milestones in 2026 across its core programs [30] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the upcoming milestones and the potential for substantial value creation from its pipeline [30][31] - The company is excited about the progress made in 2025 and the potential opportunities in 2026, emphasizing the importance of addressing unmet medical needs [30][31] Other Important Information - The company has strengthened its cash position with over $100 million from a recent capital raise and a milestone payment from Novo Nordisk [8][27] - The company plans to reduce total operating expenses to between $100 million and $110 million in 2026 [29] Q&A Session Summary Question: What is the status of the Steno-1 study data for DKA safety? - Management expects a 6-month review for the NDA resubmission and is confident in the data supporting submission and approval timelines [33][36] Question: How have the Phase 2 results accelerated partnering discussions for pilavapadin? - Discussions with partners have become more specific following the end of Phase 2 meeting, but no acceleration in discussions has been noted [38][39] Question: What are Novo Nordisk's plans for LX9851? - The company believes Novo is exploring various options for LX9851, including its use in combination therapies for obesity management [40][41] Question: Is there flexibility to start the pilavapadin study without a partner? - The company is focused on cardiometabolic opportunities and is preparing for the Phase 3 program while engaging in partnership discussions [46][48] Question: How confident is the company in achieving the enrollment target for SONATA-HCM? - Management is confident in meeting the mid-year enrollment target, with strong enrollment trends observed across all regions [60][64] Question: What changes will be made to the Phase 3 design of the pilavapadin program? - The company plans to expand enrollment criteria and enhance patient training on pain score assessments to improve consistency [67][70]

Fourth Quarter and Full Year 2025 Earnings M a r c h 5 , 2026 Forward-Looking Statements 2 • This presentation, including any oral presentation accompanying it, contains "forward-looking statements," including statements about Lexicon's strategy and operating performance and events or developments that we expect or anticipate will occur in the future, such as projections of our future results of operations or of our financial condition, the potential therapeutic and commercial potential of sotagliflozin, pi ...

Core Insights - Lexicon Pharmaceuticals has made significant progress in its pipeline and financial position, with key milestones achieved in 2025 and a strong start to 2026 [2][3] Financial Performance - Total revenues for Q4 2025 were $5.5 million, with annual revenues of $49.8 million, including $4.3 million from licensing revenue and $1.1 million from net sales of INPEFA [12] - The company reported a net loss of $15.5 million for Q4 2025, a reduction from a net loss of $33.8 million in Q4 2024, and a full-year net loss of $50.3 million compared to $200.4 million in 2024 [16] - Research and development expenses decreased to $11.3 million in Q4 2025 from $26.7 million in 2024, while full-year R&D expenses were $61.1 million, down from $84.5 million [14] - Selling, general and administrative expenses also saw a significant decrease, totaling $8.8 million in Q4 2025 compared to $32.3 million in Q4 2024, and $37.3 million for the full year versus $143.1 million in 2024 [15] Pipeline Developments - Sotagliflozin, an oral SGLT1 and SGLT2 inhibitor, has been studied in approximately 20,000 patients and is commercially available in the U.S. for heart failure as INPEFA [4] - The SONATA-HCM study, a pivotal Phase 3 trial for hypertrophic cardiomyopathy, has surpassed 50% enrollment with a target of 500 patients and is expected to complete enrollment by mid-2026 [8] - Lexicon is on track for a potential NDA resubmission for ZYNQUISTA in Type 1 Diabetes in 2026, contingent on meeting FDA requirements [8] Strategic Partnerships and Funding - The company strengthened its financial position with over $100 million in additional cash from a capital raise and a milestone payment from Novo Nordisk [3][19] - Lexicon has entered into a licensing agreement with Viatris for the commercialization of sotagliflozin outside the U.S. and Europe, with regulatory submissions planned for several markets in 2026 [7][9] Regulatory and Development Readiness - A successful End-of-Phase 2 meeting with the FDA for pilavapadin confirms its readiness for Phase 3 development, which will include placebo-controlled studies [17] - The company is actively engaged in partnership discussions to maximize the global potential of its investigational therapies [17]

Core Insights - Lexicon Pharmaceuticals Inc. (NASDAQ:LXRX) is recognized as a rapidly growing penny stock, with analysts highlighting its potential for investment [1] - Citi analyst Yigal Nochomovitz raised the price target for Lexicon from $1.90 to $2.10, maintaining a Buy rating due to an updated financial model reflecting milestones in the LX9851 partnership with Novo Nordisk [1][3] Financial Performance - In Q3 2025, Lexicon reported revenue of $14.2 million, primarily driven by $13.2 million in licensing revenue from its partnership with Novo Nordisk [2] - The company's net loss decreased to $12.8 million, or $0.04 per share, compared to a net loss of $64.8 million in the previous year [2] Research and Development Milestones - Lexicon achieved significant R&D milestones, including the completion of all IND-enabling studies for its obesity candidate LX9851, which have been submitted to Novo Nordisk for clinical development [3] - The company is advancing its heart failure medication, INPEFA, into international markets through licensee Viatris and has submitted additional data to the FDA to support the benefit-risk profile for Zynquista in type 1 diabetes [3]